Tuesday, November 28, 2017

Qool Therapeutics Gets $8M

Menlo Park-based Qool Therapeutics, which is developing non-invasive, temperature management systems aimed at treating clinical conditions in vascular surgery, cardiac arrest and trauma, has raised $8M in a Series A-1 funding round, the company said today. The funding came from Zhongji Holdings LTD/Join Medical Technology, TAMCAP LLC, BrilliMedical International Corp., BioPacific Investors, Western Technology Investment, and FundRx. The company said the funding goes towards clinical product development and for its first in-human studies. Qool says its systems could be used in treating cardiac arrest, acute myocardial infarction, stroke, traumatic brain injury, cardiogenic shock, status epilepticus, encephalitis, meningitis, burns, heat stroke, hyperthermia and sepsis, and as a protective adjunct for vascular surgery.